hypertension (Cuspidi, Ciulla, & Zanchetti, 2006) , ischaemic heart disease (Hinderer & Schenke-Layland, 2019) , aortic stenosis (Bing et al., 2019; Katbeh et al., 2018) , inherited cardiomyopathy (Gulati et al., 2013; Ho et al., 2010) , diabetes (Russo & Frangogiannis, 2016) , and ageing (Lu et al., 2017) .
Chronic kidney disease is defined as a persistent loss of renal function and is a growing global health problem, affecting~13% of the world's population (Jager & Fraser, 2017) . Renal fibrosis occurs in both the glomerulus (glomerulosclerosis) and the tubulointerstitium and is the final common pathway for a diverse range of aetiologies which lead to chronic kidney disease (including infection, ischaemia, diabetes, autoimmune disease, physical obstruction of the urinary tract and toxic or drug insults; Djudjaj & Boor, 2019; Knoppert, Valentijn, Nguyen, Goldschmeding, & Falke, 2019) . Fibrosis of the interstitium predicts the progression of chronic kidney disease to endstage renal failure and may play a role in the transition of acute to chronic renal failure (Hewitson, Holt, & Smith, 2017; Rodríguez-Iturbe, Johnson, & Herrera-Acosta, 2005) .
Despite its importance for disease, there are currently no treatments that specifically target cardiac or renal fibrosis. Of note, the majority of cardio-renal fibrotic diseases are more common with increasing age-in particular, chronic kidney disease, diastolic heart failure, atrial fibrillation, aortic stenosis, and cardiac conduction system disease (Figure 1 ; Chiao, Lakatta, Ungvari, Dai, & Rabinovitch, 2016; O'Sullivan, Hughes, & Ferenbach, 2017) . In an increasingly ageing population, the use of effective anti-fibrotic treatments will be important for increasing healthy lifespan.
| CELLULAR AND MOLECULAR MECHANISMS OF FIBROSIS
The mechanisms for fibrosis consist of a complex medley of interacting cellular and molecular systems, but a key point of convergence for all forms of fibrosis is the transdifferentiation of fibroblasts into myofibroblasts (Rockey, Bell, & Hill, 2015b; Rosenbloom et al., 2017) .
Myofibroblasts display two specific features: Firstly, they secrete extracellular matrix which constitutes fibrotic scar (predominantly type I and type III collagen and fibronectin). Secondly, they are contractile-via the expression of α-smooth muscle actin (ACTA2)thus causing tissue contraction, increased tissue stiffness, and the parenchymal distortion characteristic of fibrotic organs (Rosenbloom et al., 2017; Wynn, 2008) .
The molecular factors involved in fibrosis are wide ranging, including PDGF, connective tissue growth factor, angiotensin II and endothelin-1 (Rockey et al., 2015b; Wynn, 2008) . But the core pathway, involved in virtually all types of fibrosis, is the TGF-β signalling cascade (Meng, Nikolic-Paterson, & Lan, 2016; Rockey et al., 2015b) .
However, inhibition of TGF-β-either directly or indirectly-is associated with side effects due to its pleiotropic role across various cell types (Bierie et al., 2009; Shull et al., 1992) . Repeated efforts to target TGF-β family members in clinical trials have failed either due to lack of efficacy, likely reflecting dose-limiting toxicities, or due to on-target toxicity itself (Group, C. A. T. Trabeculectomy Study et al., 2007; Voelker et al., 2017) . More recently, trials targeting the processing of the latency-associated peptide-as an indirect means of inhibiting TGF-β with suggested less toxicity-were discontinued due to, yet again, safety issues (Keown, 2019) .
IL-11 is a less frequently studied cytokine which has only recently been shown to be an important downstream regulator of TGF-β in cardiorenal fibrosis (Schafer et al., 2017) . Here, we will suggest that treatments targeting IL-11 have the potential to more safely prevent, treat, and perhaps even reverse fibrotic cardiorenal disease.
| IL-11 IS AN IL-6 FAMILY CYTOKINE WITH DISTINCT BIOLOGICAL FUNCTIONS
The IL-6 family of cytokines includes IL-6, IL-11, IL-27, oncostatin M (OSM), leukaemia inhibitory factor (LIF), cardiotrophin-1, F I G U R E 1 Overview of heart and kidney diseases defined by fibrosis and the consequent effects on organ function cardiotrophin-like cytokine (CLCF), and ciliary neurotrophic factor (CNTF; Murakami, Kamimura, & Hirano, 2019; Rose-John, 2018 ).
These cytokines have traditionally been grouped together as they all signal via the ubiquitously expressed signalling receptor subunit glycoprotein 130 kDa (gp130). IL-6 and IL-11 form a complex with a gp130 heterodimer, whereas other members of the family form homodimers (Garbers & Scheller, 2013; Taga & Kishimoto, 1997) . This has led to a belief that the functions of some of these cytokines are partly overlapping and redundant. However, specificity is provided by unique, high-affinity receptor subunits leading to a diversity in biological function which is apparent from genetics: mutations affecting the function of the OSM-specific receptor β lead to familial primary localized cutaneous amyloidosis (Arita et al., 2008) , whereas mutations in the LIF receptor cause Stüve-Wiedemann syndrome, a severe form of bentbone dysplasia which typically causes death in early life (Dagoneau et al., 2004) . Null mutations in CNTF cause motor neuron degeneration in mice (Masu et al., 1993) but do not cause disease in humans (Takahashi et al., 1994) . While IL-6 has been very extensively studied, the functions of the other IL-6 family cytokines remain less well understood.
IL-11 is most often compared to IL-6 as both initiate signalling by forming ostensibly similar hexameric complexes with their cognate receptors and gp130. In both cases, the cytokine first binds with its "α" receptor (IL-6RA or IL-11RA) either at the membrane (classical signalling) or, at least for IL-6, in solution (trans-signalling).
This complex then interacts with gp130 molecules, triggering their dimerization and subsequent downstream signalling (Garbers & Scheller, 2013; Taga & Kishimoto, 1997) . However, important structural differences have been found between IL-6 and IL-11, suggesting that IL-11 may engage gp130 differently to IL-6, with potential consequences for downstream effects (Putoczki, Dobson, & Griffin, 2014) . Indeed, IL-6 is known to signal predominantly via the JAK/STAT pathway (Taga & Kishimoto, 1997) . However, recent work in fibroblasts found that IL-11 causes sustained ERK activation, without physiologically relevant activation of STAT Schafer et al., 2017; Widjaja, Sing, et al., 2019) . It has also been shown that IL-11 at high concentrations can activate STAT in transformed cell lines (Lu et al., 1994) and some primary cells, although some of these cell lines do not appear to express the IL-11RA, which requires further study. Importantly, IL-6RA and IL-11RA differ in their expression pattern across cell types, indeed almost mutually exclusively so in the FANTOM datasets, in support of the concept that IL-11 and IL-6 activate distinct target cell populations (Schafer et al., 2017) . IL-6RA is most highly expressed on immune cells and as such has become an important target for treating immune-mediated diseases, such as rheumatoid arthritis. IL-6RA has also been detected in transformed hepatic cells such as HepG2. In contrast, IL-11RA is most highly expressed on stromal cells including fibroblasts, vascular smooth muscle cells, adipocytes, hepatic/pancreatic stellate cells, and pericytes, as wells as on polarized cells such as hepatocytes, alveolar epithelial cells, and kidney tubular epithelial cells Schafer et al., 2017; Widjaja, Sing, et al., 2019) .
In keeping with these differences, the effect of loss-of-function mutations in the IL-6 pathway varies greatly from those in the IL-11 pathway. Humans with homozygous loss-of-function mutations in IL-6R suffer from severe immune dysregulation (Spencer et al., 2019) , and predicted loss-of-function mutations in IL-6 or IL-6R are selected against in the general population. Accordingly, one of the most frequent on-target side effects of anti-IL-6 therapy is infection (Khanna et al., 2016) . In contrast, predicted loss-of-function mutations in IL-11 or IL-11RA in the general population are not selected against and are as common as expected by chance (Karczewski et al., 2019) . Individuals with biallelic (homozygous or compound heterozygous) null mutations in IL-11RA sometimes have abnormalities of delayed tooth eruption, mild craniosynostosis, scoliosis, and joint laxity but are otherwise healthy, with no increased risk of cancer, wound healing, cardiovascular disease, immune dysfunction or infection (Keupp et al., 2013; Miller et al., 2017; Nieminen et al., 2011; Papachristoforou, Petrou, Sawyer, Williams, & Drousiotou, 2014) . It is also notable that while IL-6 is expressed in healthy adults, IL-11 is not, suggesting that IL-11 plays a limited role in healthy adult humans.
4 | DISCOVERY OF IL-11 AND DEVELOPMENT OF RECOMBINANT HUMAN IL-11 TO TREAT THROMBOCYTOPAENIA IL-11 was initially characterized as a stromal-derived cytokine able to stimulate megakaryocyte colony formation and also to exert an inhibitory action on adipogenesis in the bone marrow micro-environment (Kawashima et al., 1991; Kawashima & Takiguchi, 1992; Keller, Du, Srour, Hoffman, & Williams, 1993; Paul et al., 1990) . The initial characterization as a haematopoietic cytokine inspired studies of IL-11 on platelet production, which it was found to increase in vivo. This chance finding led to the development of recombinant human IL-11 (rhIL-11) for the treatment of chemotherapy-induced thrombocytopenia (Isaacs et al., 1997) .
However, it was later found that IL11ra1 knockout mice and humans with a null mutation in the IL11RA gene display normal blood cell counts (Brischoux-Boucher et al., 2018; Nandurkar et al., 1997) , indicating that IL-11 signalling is, in fact, redundant for normal haematopoiesis. IL-11 alone was found in some studies not to directly stimulate megakaryocytes (Teramura, Kobayashi, Hoshino, Oshimi, & Mizoguchi, 1992) , and long-term anti-IL-11 therapy in mice has no effect on platelet counts .
Following its development as a therapeutic agent in the 1990s, rhIL-11 became readily available as a tool for the scientific community and was used extensively to study the effects of rhIL-11 in preclinical rodent models. Unfortunately, as we discuss in detail below, recombinant IL-11 has species-specific activity (Schafer et al., 2017; , and the use of rhIL-11 in mice and rats has led to misunderstanding as to the true biological function of IL-11.
| REDISCOVERY OF IL-11 IN HUMAN CARDIAC FIBROBLASTS: A MASTER SWITCH FOR FIBROSIS
As discussed, TGF-β1 is a major driver of fibrosis across organs and disease aetiologies, inducing the transition of fibroblasts into activated myofibroblasts which express ACTA2 and deposit ECM (Akhurst & Hata, 2012; Rockey et al., 2015b) . However, the ability to target TGF-β1 to reduce fibrosis is limited by on-target side effects (Bierie et al., 2009; Shull et al., 1992) . Therefore, to look for potential drug targets downstream of TGF-β1 with the potential to block fibrosis while avoiding toxicities outside of the fibroblast, Schafer et al. (2017) combined quantification of fibroblast activation and ECM production with RNA sequencing of TGF-β1-stimulated, versus unstimulated, primary human cardiac fibroblast cultures. Unexpectedly, IL-11 up-regulation by more than eightfold was the dominant genome-wide response to TGF-β1 stimulation, and its expression was strongly correlated with fibroblast activation. By comparison, IL-6 expression in fibroblasts was largely unchanged by TGF-β1. Stimulating primary human fibroblasts directly with rhIL-11 was strongly pro-fibrotic-increasing ECM production and myofibroblast numbers, motility, contraction, and invasion. Further in vitro studies showed that IL-11 protein secretion from primary cardiac fibroblasts is a common feature of stimulation by diverse pro-fibrotic stimuli, including PDGF, OSM, angiotensin II, bFGF, endothelin-1, IL-13, and connective tissue growth factor ( Figure 2 ). Finally, the ability of all of these factors (and TGF-β1) to activate fibroblasts and ECM secretion can be blocked by antibodies against IL-11/IL-11RA.
| IL-11 SIGNALS VIA THE ERK PATHWAY IN FIBROBLASTS TO ACTIVATE PRO-FIBROTIC COMPONENTS POST-TRANSCRIPTIONALLY
In contrast to TGF-β, which has profound effects on transcription, RNA-seq data have consistently shown negligible differences in mRNA levels following IL-11 stimulation of fibroblasts Schafer et al., 2017) . This is somewhat unexpected, as both IL-6 and IL-11 signal via a gp130 homodimer, which results in canonical JAK/STAT activation downstream of IL-6 to initiate a proinflammatory RNA expression profile. In contrast to this, in fibroblasts IL-11 was found to drive pro-fibrotic gene expression at the posttranscriptional level, which results in myofibroblast activation and secretion of ECM proteins. This effect appears to be dependent on the phosphorylation of ERK and its downstream targets-including 40S ribosomal protein S6 kinase (RSK) and eurkaryotic translation initiation factor 4E (eIF4E)-which are involved in activation of protein translation (Schafer et al., 2017) . MEK/ERK inhibitors (U0126 and PD98509) block the pro-fibrotic effect of IL-11 on fibroblasts, and TGF-β stimulation is unable to activate ERK in fibroblasts isolated from IL-11ra1 −/− mice Schafer et al., 2017) . Interestingly, STAT3-considered the canonical signalling pathway for IL-11is only mildly and transiently phosphorylated after IL-11 stimulation in primary fibroblasts, and this has little measurable transcriptional consequences. Further insights into IL-11 signalling mechanisms have recently been elucidated by a study suggesting that IL-11 may mediate translation of proline-rich proteins (such as collagen or IL-11 itself) via activation of glutamyl-prolyl-tRNA synthetase (EPRS) (Wu, Subbaiah, Xie, Jiang, & Mickelsen, 2019) .
In primary human cardiac fibroblasts, the post-transcriptional gene expression programme dependent on autocrine IL-11 signalling is a necessary requirement for fibrogenesis, downstream of multiple pro-fibrotic stimuli ( Figure 2 ). Previous studies suggest that IL-11 activates myofibroblasts and results in ECM secretion posttranscriptionally via ERK ( Figure 3 ), but other non-canonical pathways may also play a role. It is also unclear whether signalling downstream of IL-11 is different across cell types and states. In addition to stromal cells, many polarized and epithelial cells-such as cardiac myocytes, hepatocytes, alveolar, and tubular epithelial cells-also express IL-11RA and pathways of activation following IL-11 binding may vary.
| ROLE OF IL-11 IN EPITHELIAL VERSUS STROMAL CELLS
In this review, we concentrate mainly on the pro-fibrotic role of IL-11 in stromal cells (fibroblasts). However, it should be noted that there is evidence of IL-11 release from and signalling within epithelial cells, typically in response to acute injury. For example, respiratory syncytial virus is a potent stimulus for IL-11 secretion from lung epithelium (Einarsson, Geba, Zhu, Landry, & Elias, 1996; Elias et al., 1994) . Similarly, IL-11 is released from hepatocytes after injury with paracetamol F I G U R E 2 In fibroblasts, IL-11 acts at a point of signalling convergence downstream of multiple and diverse stimuli and is the nexus between pro-fibrotic initiating factors and organ fibrosis. ANG II, angiotensin II; bFGF, basic FGF; CTGF, connective tissue growth factor; ET-1, endothelin 1; OSM, oncostatin M (acetaminophen) and can then act in an autocrine manner to induce ROS and cell death . In epithelial cells isolated from lung organoid models of idiopathic pulmonary fibrosis, IL-11 expression is increased and is hypothesized to have a role in epithelial-to-mesenchymal transition and the early initiation of fibrosis (Strikoudis et al., 2019) . In the kidney, the response of tubular epithelial cells to injury are now thought to have a crucial role in the initiation of fibrosis and the transition from acute to chronic renal failure (Qi & Yang, 2018) . Given the large and relatively early increases in IL-11 expression observed in whole kidney tissue following injury (Table 1 and discussed below), there may be an important role for IL-11 signalling in tubular epithelial cells. Exploring this should be a priority for future study.
| IL-11 IS ASSOCIATED WITH FIBROTIC CARDIOVASCULAR DISEASE IN MOUSE MODELS AND HUMAN PATIENTS
In the heart, IL-11RA is expressed on both fibroblasts and cardiomyocytes (Kimura et al., 2007; FANTOM Consortium and the RIKEN PMI and CLST [DGT] et al., 2014) . As mentioned, the dominant transcriptional response to TGF-β1 stimulation of human atrial fibroblasts is IL-11 expression (Schafer et al., 2017) . Several studies have explored the association of IL-11 and cardiovascular disease across species. These are summarized in Table 1 and discussed below.
Following myocardial infarction in mice, IL-11 expression is upregulated >50-fold after 24 hr, and increased levels are maintained for at least 14 days (Obana et al., 2010) . Similarly, in rats fed a high-salt diet-resulting in hypertension, cardiac fibrosis, and heart failure with preserved ejection fraction-cardiac IL-11 expression is significantly increased (Zhou et al., 2019) . In two other models of fibrotic heart disease-continuous angiotensin II infusion and transverse aortic constriction-increased levels of IL-11 protein are seen in the heart (Schafer et al., 2017) .
In humans, serum IL-11 is increased in patients with congestive cardiac failure, correlates with the severity of heart failure symptoms, and predicts cardiac events including cardiovascular death and heart failure rehospitalization (Ye et al., 2019) . Similarly, serum IL-11 is raised in patients with coronary heart disease (Liu et al., 2015) , and both serum and aortic IL-11 are increased in patients with thoracic aortic dissection (Xu et al., 2018) . Intriguingly, common side effects of rhIL-11 in patients being treated for thrombocytopenia include atrial arrhythmia, pulmonary congestion, raised brain natriuretic peptide levels, and, in some cases, left ventricular failure (Liu et al., 2019; Smith, 2000) , though this is at least partly related to acute sodium and water retention (Dykstra et al., 2000) .
In summary, increased IL-11 levels are found in primary human cells subjected to pro-fibrotic stimuli, in the hearts of mice with fibrotic heart disease and in the serum and tissue of patients with cardiovascular disease. These associations suggest that IL-11 may have a pathogenic role in fibrotic cardiac disease. An alternative explanation-which is prevalent in the literature-is that IL-11 is protective against fibrotic heart disease and is induced as a natural suppressor of fibrosis. In the next section, we discuss how earlier work studying the effect of recombinant human IL-11 (rhIL-11) on the mouse or rat heart suggested the latter conclusion, whereas more recent work using species-matched IL-11 has revealed the true pathophysiological role of IL-11 as a pro-fibrotic cytokine.
| SPECIES-SPECIFIC RECOMBINANT IL-11 HAS A PRO-FIBROTIC EFFECT ON THE HEART
In 2007, Kimura et al. reported that pretreatment with an IL-11 infusion had a protective and anti-fibrotic effect in mice subjected to 60 min of cardiac ischaemia followed by reperfusion. Subsequent work found similar results in permanent left coronary artery ligation (Obana et al., 2010) , in post-reperfusion treatment (Obana et al., 2012) and in a cold F I G U R E 3 Putative IL-11 signalling pathways in fibroblasts. In contrast to TGFβ (and other upstream pro-fibrotic stimuli), IL-11 has a negligible effect on transcription in fibroblasts. Instead, IL-11 signals via ERK to enhance translation of pro-fibrotic proteins while also possibly employing EPRS activation to translate proline rich proteins where ribosomes can stall on proline repeat regions (PRRs). ACTA2, actin α2 (aka smooth muscle actin); COL1A2, collagen type 1 α2; eIF4E, eurkaryotic translation initiation factor 4E; EPRS, glutamyl-prolyl-tRNA synthetase; gp130, glycoprotein 130; IL-11RA: IL-11 receptor α; MNK, MAPK-interacting serine/threonineprotein kinase 1; p90RSK, p90 ribosomal S6 kinase; POSTN, periostin; TGFβ Rec, TGF β receptor T A B L E 1 Summary of studies with data on the role of IL-11 in cardiac or renal fibrosis 
ischaemia model designed to mimic the conditions of cardiac transplant (Tamura et al., 2018) . However, in all cases, mice or rats received recombinant human-rather than mouse or rat-IL-11 at high doses.
These earlier data directly contrast the more recent results discussed in the previous section, which showed a strong pro-fibrotic effect of recombinant human IL-11 when applied to primary human myofibroblasts (Schafer et al., 2017) . To explore this apparent contradiction, Schafer et al. (2017) generated recombinant mouse IL-11 (rmIL-11) and compared the effects of this to rhIL-11 on mouse fibroblasts-rmIL-11 produced a strong pro-fibrotic effect at a physiological dose, whereas rhIL-11 had little effect, even at very high doses.
Importantly, species-matched rhIL-11 on human fibroblasts or rmIL-11 on mouse fibroblasts resulted in activation of non-canonical signalling pathways, predominantly via the phosphorylation of ERK.
Conversely, STAT3 activation, although transiently mildly elevated, had no downstream effects on transcription. This is in contrast to the signalling seen in previous studies where species-discordant rhIL-11 was administered to mice.
Recent work in hepatocytes has shed further light on the molecular underpinning of species-specific IL-11 effects . Similar to myofibroblasts, rmIL-11 stimulated the ERK (and JNK) pathway in mouse hepatocytes whereas rhIL-11 had no effect in mouse cells. The activation of non-canonical signalling pathways (i.e., not STAT) was also observed when species-matched rhIL-11 was used with primary human cells. Interestingly, despite not activating mouse signalling pathways, surface plasmon resonance experiments demonstrated that rhIL-11 binds to the mouse IL-11ra1 with a slightly higher affinity than rmIL-11. Competition ELISA showed that rhIL-11 is a highly effective blocker of mouse IL-11 binding to IL-11ra1 and that rhIL-11 actually inhibits rmIL-11 activity in murine hepatocytes. Thus-paradoxically-rhIL-11 acts as an inhibitor of endogenous IL-11 in mice, a result which may explain the protective effect of rhIL-11 in rodent models of IL-11-mediated disease .
Expanding on the in vitro results, Schafer et al. (2017) tested the effect of injecting recombinant mouse IL-11 into healthy mice. In contrast to the earlier studies that had used human IL-11 in the mouse, this resulted in cardiac and renal fibrosis. Injection of rmIL-11 to the mouse increased epicardial fibroblast activation, a hallmark of fibrosis in myocardial infarction, and resulted in worsening of left ventricular function (Schafer et al., 2017) .
Next, the in vivo effects of fibroblast-specific IL-11 expression were investigated by generating murine Il11-transgenic mice crossed with Tam-inducible Col1a2-Cre mice: Within 2 weeks, there was widespread activation of cardiac and renal fibroblasts and accumulation of collagen. This was accompanied by a reduction in cardiac and renal function and increased serum TGF-β1 (Schafer et al., 2017) .
Together, these results show that IL-11 biology is conserved across species, but the role of endogenous IL-11 cannot be inferred from the use of recombinant human IL-11 on rodent cells or tissues.
The effect of species-matched IL-11, either administered exogenously or overexpressed endogenously, is pro-fibrotic in the heart. Combined with the observational data of increased IL-11 in multiple animal models and human cardiac disease, this suggests a causative role for IL-11 in fibrotic heart disease, rather than the previously assumed protective, anti-inflammatory, and anti-fibrotic role.
| IL-11 IS ASSOCIATED WITH RENAL INJURY IN DIVERSE ANIMAL MODELS AND IN HUMAN PATIENTS
Fibrotic renal injury in patients can result from diverse insults. Experiments with animal models across different species (mouse, rat, and carp) have found an association between IL-11 and the varied renal insults, including ischaemia (Grgic et al., 2014; Lemay et al., 2000) , drug or chemical toxicity (Mitazaki et al., 2009; Schafer et al., 2017) , hypertension (Harlan et al., 2018; Menendez-Castro et al., 2019) , diabetes (Harlan et al., 2018) , infection (Xu et al., 2014) , and physical obstruction of the urinary tract (Grgic et al., 2014) . These studies are summarized in Table 1 .
In humans, few studies to date have investigated the role of IL-11 in renal disease. However, a study in paediatric patients found a highly significant correlation between urinary IL-11 protein and mRNA levels and proteinuria in patients with IgA nephropathy or lupus nephritis (Chien et al., 2006) . In primary human renal epithelial cells, adenovirus-mediated expression of GADD45γ (a protein highly upregulated in renal tissue injured by urinary tract obstruction) results in a 6.7-fold up-regulation of IL-11 expression (Shin, Kim, Lim, Yim, & Kim, 2008) . A recent study by Bigaeva et al. (2019) used RNA-seq in cultured precision cut tissue slices (PCTS)-an in vitro model of fibrosis which maintains the complex three-dimensional structures of organs-to assess the fibrosis-associated transcriptomic response in healthy mouse, healthy human, and diseased human tissues. They found that IL-11 was one of the few genes to be consistently upregulated in PCTS across species and organs (including kidney, liver, ileum, and colon; cardiac tissue was not assessed). In particular, IL-11 was one of the most up-regulated genes (5-to 10-fold) in kidney PCTS from healthy mouse, healthy human, and diseased human (endstage renal failure) donors.
| SPECIES-MATCHED EXOGENOUS IL-CAUSES KIDNEY FIBROSIS AND DYSFUNCTION
Similar to work on cardiac fibrosis, the role of IL-11 in kidney disease has likely been confounded and confused by the use of recombinant human IL-11 (rhIL-11) in rodent models. For example, it has been shown that rhIL-11 protects from renal-ischaemia reperfusion injury (Lee et al., 2012) and suppresses extracellular matrix deposition and glomerular injury in experimental glomerulonephritis (Lai et al., 2001 (Lai et al., , 2005 .
In contrast, more recent work has shown that exogenous administration or overexpression of mouse IL-11 in the mouse causes, rather than inhibits, renal fibrosis. Three weeks of daily rmIL-11 treatment in mice activated fibroblasts in the renal interstitium, resulted in deposition of collagen and caused impairment of renal function (Schafer et al., 2017) . Similarly, 2 weeks of inducible IL-11 overexpression in a fibroblast-specific manner in murine Il11-transgenic mice crossed with inducible Col1a2-Cre mice caused renal fibrosis and an increase in serum urea and creatinine, indicating renal dysfunction (Schafer et al., 2017 (Nandurkar et al., 1997) .
The similarities in the human and mouse IL-11RA null phenotype suggest strong conservation of IL-11 function across mammalian species and that proof-of-concept studies targeting IL-11 in mice could provide valuable data that translate to humans. Furthermore, the lack of overt adverse post-developmental consequences of IL-11RA deletion in either mice or humans suggests that targeting IL-11 signalling could be a safe means to treat fibrosis in adult mammals.
To investigate this further, IL-11ra1 −/− mice were compared to wild-type controls in three independent models of cardiac and renal fibrosis (Schafer et al., 2017) . Following angiotensin II infusion or transverse aortic constriction, IL-11ra1 −/− mice had less cardiac fibrosis than wild-type mice, an effect which was independent of loading conditions. Similarly, after folic acid-induced kidney injury, IL-11ra1 −/− mice had reduced renal fibrosis. Deletion of IL-11ra1 signalling resulted in reduced ERK signalling across all models tested.
13 | NEUTRALIZING IL-11 ANTIBODIES ARE ANTI-FIBROTIC Our group genetically immunized mice with IL-11 to generate neutralizing IL-11 antibodies. Clones were then screened for neutralization activity using fibroblast transformation as a readout. Clones X203
(anti-IL-11) and X209 (anti-IL-11ra1) effectively blocked the fibrotic response in mice and human cells and were chosen for preclinical testing in mouse models .
Neutralizing anti-IL-11 antibodies markedly reduced the pro-fibrotic effect of TGF-β stimulation on atrial fibroblasts across a wide range of assays, including myofibroblast activation, ECM production, and gel contraction and cell migration Schafer et al., 2017) .
In animal models, clones X203 and/or X209 have been shown to prevent or reverse fibrosis in the lung and liver . Studies investigating the effects of anti-IL-11 therapy on cardiac or renal fibrosis are ongoing and are expected to be reported in the near future.
| CONCLUSIONS
Fibrosis is a key and common driver of cardiac and renal failure, which account for a large proportion of global morbidity and mortality. As fibrotic diseases are more prevalent in older individuals, this burden will increase as populations age. Therefore, new treatments that safely and specifically target cardiorenal fibrosis are needed, and this represents an unmet medical need. This is especially so, given that recent trials have now clearly shown that targeting TGF-β directly, or indirectly via integrins, is toxic and ineffective and new drug targets are needed.
IL-11 up-regulation-acting downstream of TGF-β and other profibrotic factors-appears to be a unifying feature underlying cardiorenal fibrotic diseases. Earlier work using human IL-11 in murine models led to the conclusion that its up-regulation in fibroinflammatory diseases was a protective response, a compensatory mechanism to prevent runaway fibrosis. More recent studies have questioned this conclusion: The true endogenous role of IL-11 appears pro-fibrotic, resulting in the activation of myofibroblasts, inflammation, the deposition of ECM and ultimately organ dysfunction and failure.
From a therapeutic point of view, biallelic IL-11RA null mutations in mice and humans are tolerated in adults, which suggests inhibiting IL-11 signalling may be safe, but this remains to be proven. Future work exploring the effect of anti-IL-11 therapies in animal models and, ultimately, in human clinical trials will determine if its potential can be realized to help the millions of patients worldwide suffering with fibrotic diseases of the kidney or heart.
| Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMA-COLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2019/20 (Alexander, Fabbro et al., 2019a, b; . 
